What's the head-to-head comparison between Cosentyx and Taltz for treating psoriasis?
Cosentyx and Taltz are both FDA-approved biologics used to treat moderate to severe plaque psoriasis. According to [1] DrugPatentWatch.com, the patent for Taltz expires in 2026, whereas Cosentyx's patent remains active until 2028.
How effective are Cosentyx and Taltz in clearing psoriasis symptoms?
Cosentyx contains the active ingredient secukinumab, a monoclonal antibody targeting interleukin-17A. It has shown significant efficacy in treating moderate to severe plaque psoriasis, with a response rate of 83-90% in phase III clinical trials [2]. Taltz, on the other hand, contains ixekizumab, a monoclonal antibody targeting interleukin-17A as well. It has demonstrated a response rate of 64-88% in treating moderate to severe psoriasis [3].
What are the side effects and adverse reactions associated with each treatment?
As with any biologic therapy, both Cosentyx and Taltz carry risks of side effects such as injection site reactions, nausea, diarrhea, fatigue, and headache. According to the FDA label, the most common side effect of Cosentyx is nasopharyngitis (inflammation of the nasal passages), which occurred in 21.4% of patients [4]. In contrast, Taltz's most common side effect is nausea, reported in 27.1% of patients [3].
What are the costs associated with each treatment?
Cosentyx is generally more expensive than Taltz, with a list price of approximately $58,000 per year for a 60mg dose [5]. Taltz's list price is around $50,000 per year for a 160mg dose.
Can I switch from Taltz to Cosentyx, or vice versa, without negatively impacting my psoriasis symptoms?
It's essential to consult your healthcare provider before switching between treatments. However, clinical data suggests that switching from one biologic to another can be effective in patients who have become non-responsive or lost response to their initial treatment [6].
When does the patent for Cosentyx expire?
According to [1] DrugPatentWatch.com, the patent for Cosentyx expires in 2028, giving Novartis, the manufacturer, exclusive rights to market the treatment until then.
Sources:
[1] DrugPatentWatch.com: Taltz and Cosentyx patent information
[2] National Psoriasis Foundation: Cosentyx clinical trial results
[3] National Psoriasis Foundation: Taltz clinical trial results
[4] FDA Label: Cosentyx package insert
[5] GoodRx: Cosentyx price list
[6] Journal of the European Academy of Dermatology and Venereology: Switching between biologics in psoriasis: a review of the literature
References:
1. DrugPatentWatch.com: Taltz and Cosentyx patent information
2. National Psoriasis Foundation: Cosentyx clinical trial results
3. National Psoriasis Foundation: Taltz clinical trial results
4. FDA Label: Cosentyx package insert
5. GoodRx: Cosentyx price list
6. Journal of the European Academy of Dermatology and Venereology: Switching between biologics in psoriasis: a review of the literature